T cell receptor-engineered T cells for hepatocellular carcinoma: next steps and future perspectives
Open Access
- 12 October 2026
- journal article
- review article
- Published by Springer Nature in Clinical Cancer Bulletin
- Vol. 5 (1) , 23
Abstract
Hepatocellular carcinoma (HCC) accounts for a substantial proportion of cancer mortality worldwide, and clinical outcomes remain poor for patients with advanced disease. T cell receptor-engineered T cells (TCR-T) represent an attractive immunotherapeutic modality because they can recognize peptide epitopes derived from intracellular tumor proteins and displayed on the cell surface by major histocompatibility complex molecules. This review critically summarizes recent progress in TCR-T therapy for HCC, with particular emphasis on innovations in TCR engineering. We survey the current landscape of targetable antigens in HCC and current approaches for identifying therapeutic TCR candidates, followed by a discussion of TCR-T and review their major safety and toxicity concerns. Importantly, we discuss the key challenges that limit the clinical efficacy, particularly the immunosuppressive tumor microenvironment, antigen heterogeneity, HLA restriction, and limited T cell persistence. We further highlight emerging strategies to enhance therapeutic efficacy and safety, including genetic engineering, metabolic and functional optimization, combinational approaches, and controllable safety mechanisms. Special considerations regarding TCR-T therapy for HCC recurrence after liver transplantation are also discussed. Finally, we outline future directions centered on refined target selection, artificial intelligence-assisted TCR discovery and design, scalable manufacturing, biomarker-driven patient selection, and rigorous safety evaluation. These insights provide a structured perspective on the current status of TCR-T therapy and the key steps required to facilitate its clinical translation in HCC.Keywords
Funding Information
- Shanghai Municipal Health Commission (2024CXJQ02)
This publication has 220 references indexed in Scilit:
- NY‐ESO‐1 antigen: A promising frontier in cancer immunotherapyClinical and Translational Medicine, 2024
- A novel adoptive synthetic TCR and antigen receptor (STAR) T‐Cell therapy for B‐Cell acute lymphoblastic leukemiaAmerican Journal of Hematology, 2022
- Hypoxia‐driven immunosuppression by Treg and type‐2 conventional dendritic cells in HCCHepatology, 2022
- Immunological alterations after immunotherapy with short lived HBV‐TCR T cells associates with long‐term treatment response in HBV‐HCCHepatology Communications, 2021
- Trends in Hepatocellular Carcinoma Incidence and Risk Among Persons With HIV in the US and Canada, 1996-2015JAMA Network Open, 2021
- Immunosuppressive Drug‐Resistant Armored T‐Cell Receptor T Cells for Immune Therapy of HCC in Liver Transplant PatientsHepatology, 2020
- 4‐1BB Delineates Distinct Activation Status of Exhausted Tumor‐Infiltrating CD8+ T Cells in Hepatocellular CarcinomaHepatology, 2019
- Tuning T‐Cell Receptor Affinity to Optimize Clinical Risk‐Benefit When Targeting Alpha‐Fetoprotein–Positive Liver CancerHepatology, 2018
- Identification of α‐fetoprotein‐specific T‐cell receptors for hepatocellular carcinoma immunotherapyHepatology, 2018
- Different affinity windows for virus and cancer‐specific T‐cell receptors: Implications for therapeutic strategiesEuropean Journal of Immunology, 2012